Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.59 |
| ▸ | RAB9A | P51151 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10216303 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2RAB9AMAPTMCHR1NPC1 | |
| SCHEMBL10216312 | 0.94 | MCHR1 (0.58) | SMN1; SMN2RAB9AMAPTMCHR1NPC1 | |
| SCHEMBL566983 | 0.94 | MCHR1 (0.58) | SMN1; SMN2RAB9AMAPTMCHR1NPC1 | |
| SCHEMBL566513 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2RAB9AMAPTMCHR1NPC1 | |
| SCHEMBL10269772 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2RAB9AMAPTMCHR1NPC1 | |
| SCHEMBL566525 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2RAB9AMAPTMCHR1NPC1 | |
| SCHEMBL10270226 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2RAB9AMAPTMCHR1NPC1 | |
| SCHEMBL566510 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2RAB9AMAPTMCHR1NPC1 | |
| SCHEMBL567139 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2RAB9AMAPTMCHR1NPC1 | |
| SCHEMBL566523 | 0.94 | SMN1; SMN2 (0.59) | SMN1; SMN2RAB9AMAPTMCHR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383647-B2 | Quinoline derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-26 | — | — | US | disclosed |
| US-8383647-B2 | Quinoline derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-26 | — | — | US | disclosed |
| US-20120035213-A1 | Quinoline derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| US-20120035213-A1 | Quinoline derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-02-09 | — | — | US | disclosed |
| EP-2392573-A1 | QUINOLINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2011-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035213-A1 | Quinoline derivative | MC1R, MCHR1, MCHR2 | SMN1; SMN2 3674/4885RAB9A 578/4885MAPT 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.